Eevia Health Plc releases a new scientific article on the BioMAP study for the data and results relating to Feno-Sambucus® Organic, Eevia's organic Elderberry extract product line
Eevia Health Plc ("Eevia" or "The Company") has released a scientific article on the results of the recently completed BioMAP study that was done with Eurofins. The new article only deals with results regarding the Feno-Sambucus® Organic product line, an organically certified and trade-name-protected product line of elderberry extract.
The scientific article sums up the results that were achieved in the BioMAP study. BioMAP is a phenotypic profiling platform run by Eurofins. The receipt of the overall study report was reported on September 11, 2023 in the following press release: Eevia Health Plc confirms a top-ranking performance of key products in a broad scientific study by Eurofins, comparing against competitor alternatives - Eevia Health (cision.com)
The new article focuses on the results achieved on the Elderberry extract. The Feno-Sambucus Organic is sold in concentrations of 30%, 17%, 14% and 7% anthocyanins.
The article is a way of disseminating the results from the study to the nutraceutical market. It is an essential action to bring forward knowledge of and interest in the effects of the product. By taking a scientific approach by substantiating effects in relevant biological contexts, such as human primary cells, Eevia Health may gain more interest and lower the threshold for brand owners to include the product in their portfolios. It also steers use of resources and creates a more entrenched position as a provider of arctic polyphenols.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.
Om Eevia Health
Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.